Volume 16, Issue 12, Pages (December 2008)

Slides:



Advertisements
Similar presentations
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Advertisements

Genetic Inactivation of RelA/p65 Sensitizes Adult Mouse Hepatocytes to TNF-induced Apoptosis In Vivo and In Vitro  Fabian Geisler, Hana Algül, Stephan.
An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis  Li-Wen Liu, Tomoyuki Nishikawa,
Genetic Inactivation of RelA/p65 Sensitizes Adult Mouse Hepatocytes to TNF-induced Apoptosis In Vivo and In Vitro  Fabian Geisler, Hana Algül, Stephan.
Volume 17, Issue 9, Pages (September 2009)
Volume 70, Issue 6, Pages (September 2006)
Volume 134, Issue 1, Pages (January 2008)
Ashley L Cooney, Brajesh K Singh, Patrick L Sinn  Molecular Therapy 
Volume 18, Issue 5, Pages (May 2010)
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia by Edwin Bremer, Bram ten Cate, Douwe F. Samplonius,
Volume 63, Issue 1, Pages (January 2003)
Volume 15, Issue 12, Pages (December 2007)
Volume 10, Issue 6, Pages (December 2004)
Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer  Tadaaki Yamada, MD, PhD, Shinji Takeuchi,
Volume 6, Issue 2, Pages (August 2002)
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models  Josephine Hai, PhD, Shingo Sakashita,
Volume 120, Issue 5, Pages (April 2001)
Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity  Tina.
Volume 140, Issue 2, Pages e4 (February 2011)
BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non- small Cell Lung Carcinoma In Vitro  Wenyan Li, MD, PhD, Bo Li, MD,
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Volume 19, Issue 1, Pages (January 2011)
Volume 20, Issue 12, Pages (December 2012)
Volume 24, Issue 9, Pages (September 2016)
Min Qin, Aslan Pirouz, Myung-Hwa Kim, Stephan R. Krutzik, Hermes J
Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”  Andreas A Hombach, Gunter.
Molecular Therapy - Oncolytics
Volume 125, Issue 1, Pages (July 2003)
Volume 15, Issue 5, Pages (May 2007)
Volume 16, Issue 11, Pages (November 2008)
Min Qin, Aslan Pirouz, Myung-Hwa Kim, Stephan R. Krutzik, Hermes J
Volume 21, Issue 4, Pages (April 2013)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Volume 20, Issue 12, Pages (December 2012)
Molecular Therapy - Oncolytics
Volume 21, Issue 11, Pages (November 2013)
All-Trans-Retinoic Acid Induces Interleukin-8 via the Nuclear Factor-κB and p38 Mitogen-Activated Protein Kinase Pathways in Normal Human Keratinocytes 
Molecular Therapy - Nucleic Acids
Volume 22, Issue 5, Pages (May 2014)
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Volume 19, Issue 5, Pages (November 2003)
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas
Volume 19, Issue 10, Pages (October 2011)
Arsenic Induces Tumor Necrosis Factor α Release and Tumor Necrosis Factor Receptor 1 Signaling in T Helper Cell Apoptosis  Hsin-Su Yu, Gwo-Shing Chen 
Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System  Haoran Xin, Mingxing Lei, Zhihui Zhang, Jie Li, Hao Zhang,
Volume 16, Issue 6, Pages (June 2008)
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone
Volume 22, Issue 1, Pages (January 2014)
Volume 5, Issue 6, Pages (June 2002)
Volume 20, Issue 1, Pages (January 2012)
Volume 19, Issue 6, Pages (June 2011)
Volume 20, Issue 5, Pages (May 2012)
Volume 18, Issue 3, Pages (March 2010)
Valerie R. Wiersma, Marco de Bruyn, Robert J
Volume 10, Issue 6, Pages (December 2004)
Volume 18, Issue 3, Pages (March 2010)
Arsenic Induces Human Keratinocyte Apoptosis by the FAS/FAS Ligand Pathway, Which Correlates with Alterations in Nuclear Factor-κB and Activator Protein-1.
Volume 23, Issue 3, Pages (March 2015)
Volume 19, Issue 3, Pages (March 2011)
Volume 21, Issue 11, Pages (November 2013)
Volume 21, Issue 4, Pages (April 2013)
Jennifer Altomonte, Sabrina Marozin, Roland M Schmid, Oliver Ebert 
Volume 20, Issue 4, Pages (April 2012)
Volume 3, Issue 5, Pages (May 2001)
Volume 23, Issue 4, Pages (April 2015)
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy  Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath.
Volume 18, Issue 10, Pages (October 2010)
Volume 15, Issue 2, Pages (February 2007)
Presentation transcript:

Volume 16, Issue 12, Pages 1919-1926 (December 2008) Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein  Edwin Bremer, Gooitzen M van Dam, Marco de Bruyn, Manon van Riezen, Marike Dijkstra, Gera Kamps, Wijnand Helfrich, Hidde Haisma  Molecular Therapy  Volume 16, Issue 12, Pages 1919-1926 (December 2008) DOI: 10.1038/mt.2008.203 Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 1 Schematic representation of the mechanism of action of scFv425:sTRAIL. Binding of scFv425:sTRAIL to the epidermal growth factor receptor (EGFR), via antibody fragment scFv425, inhibits mitogenic signaling of the active EGFR dimer. Consequently, the cell is sensitized to induction of apoptosis by TRAIL. In addition, scFv425-mediated binding immobilizes soluble scFv425:sTRAIL on the cell surface of EGFR-positive tumor cells and converts soluble scFv425:sTRAIL into a membrane-bound form. This membrane-bound from of TRAIL can efficiently cross-link and activate the agonistic TRAIL receptors TRAIL-R1 and TRAIL-R2, resulting in the induction of apoptosis. TM, transmembrane. Molecular Therapy 2008 16, 1919-1926DOI: (10.1038/mt.2008.203) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 2 EGFR-restricted induction of apoptosis by adenovirally produced scFv425:sTRAIL. (a) Cell death induced by Ad-scFv425:sTRAIL shown by MTS assay. RC21.luc cells were infected Ad-scFv425:sTRAIL or Ad-Luciferase at varying multiplicity of infections (MOIs). At 6 days after infection, loss of viability was quantified by MTS assay. (b) RC21 cells were infected with Ad-scFv425:sTRAIL or Ad-Luciferase (MOI 100), after which cell viability was determined at various time points. (c) RC21.luc cells were infected with Ad-scFv425:sTRAIL or Ad-Luciferase (MOI 100), after which DNA was isolated at day 6 of infection and evaluated for apoptotic DNA fragmentation. (d) Supernatant produced by Ad-scFv425:sTRAIL–infected RC21.luc cells was used to treat noninfected RC21.luc cells in the presence or absence of TRAIL-neutralizing mAb 2E5 or EGFR-blocking mAb 425. (e) RC21.luc cells were seeded in a trans-well system, after which cells in the lower compartment were treated with Ad-scFv425:sTRAIL at varying MOI or Ad-Luciferase at an MOI of 100. After 6 days, induction of apoptosis in both infected and noninfected RC21.luc target cells was analyzed by MTS assay. Values are representatives of three independent experiments. Molecular Therapy 2008 16, 1919-1926DOI: (10.1038/mt.2008.203) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 3 Efficient production and secretion of scFv425:sTRAIL upon Ad-scFv425:sTRAIL infection of nude mice. (a) Mice (n = 3) were infected with control adenovirus Ad-Luciferase and were imaged for bioluminescence 3 days after infection. A representative picture of bioluminescence (ph/sec/cm2/sr) after Ad-Luciferase infection is given. (b) Mice were infected with saline or low and high dose of Ad-scFv425:sTRAIL (109 and 1010 vp, respectively). After 3 days, concentration of scFv425:sTRAIL in plasma was determined by TRAIL ELISA. (c) RC21.luc cells were treated with plasma obtained from mice treated with saline, Ad-Luciferase, Ad-scFv425:sTRAIL (109 vp), or Ad-scFv425:sTRAIL (1010 vp). After 16 hours, induction of apoptosis was assessed by Δψ. (d) RC21.luc cells were treated with plasma obtained from mice infected with high-dose Ad-scFv425:sTRAIL in the presence or absence of TRAIL-neutralizing mAb 2E5 or EGFR-blocking mAb 425. Apoptosis was assessed by Δψ. Molecular Therapy 2008 16, 1919-1926DOI: (10.1038/mt.2008.203) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 4 No detectable liver damage after infection with Ad-scFv425:sTRAIL. (a) A representative picture of an isolated liver after Ad-scFv425:sTRAIL (1010 vp) infection. (b) Isolated livers of saline, low- and high-dose Ad-scFv425:sTRAIL-treated mice were analyzed for caspase-3/-7 activity. As positive control for liver caspase-3–7 activation, mice were treated with Flag-FasL secondarily cross-linked with anti-Flag mAb M2. Values are represented as relative light units per mg of liver. Normal liver histology, as determined by hematoxylin and eosin staining upon (c) saline treatment, (d) Ad-scFv425:sTRAIL (109 vp)-treated and (e) in Ad-scFv425:sTRAIL (1010 vp)-treated mice. Original magnification ×200. (f) Primary human hepatocytes (PHHs) were infected with Ad-scFv425:sTRAIL (MOI 100), Ad-Luciferase (MOI 100), or treated with killer-FasL (5 µg/ml). Viability at 3 days after infection was measured using MTS assay. (g) PHHs were treated for 16 hours with plasma obtained from mice infected with Ad-scFv425:sTRAIL (1010 vp), yielding a concentration of 5 µg/ml, saline control, or killer-FasL (5 µg/ml). Apoptosis was assessed by Δψ. Molecular Therapy 2008 16, 1919-1926DOI: (10.1038/mt.2008.203) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 5 Ad-scFv425:sTRAIL infection eradicates established RC21.luc xenografts in nude mice. Nude mice with established IP RC21.luc xenografts were treated with (a) saline, (b) Ad-scFv425:sTRAIL (109 vp), (c) Ad-scFv425:sTRAIL (1010 vp). Tumor size was monitored real-time using bioluminescence imaging. The luminescence image was merged with the reference image to create an overlay image that enables anatomical localization. Images were displayed and quantified in log radiance (photons/s/cm2/sr), enabling absolute comparison between bioluminescent images across different treatment groups. Mice treated with saline and low-dose Ad-scFv425:sTRAIL were killed after 32 days. Mice treated with high dose of Ad-scFv425:sTRAIL were killed at day 64. The two panels in a, b and c show the variability in tumor size within each treatment group at the start of treatment. Molecular Therapy 2008 16, 1919-1926DOI: (10.1038/mt.2008.203) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 6 Ad-scFv425:sTRAIL infection eradicates established RC21.luc xenografts in nude mice. (a) Graph of tumor size in mice treated with saline, Ad-scFv425:sTRAIL (109 vp), and Ad-scFv425:sTRAIL (1010 vp). Tumor size was monitored using bioluminescence imaging and is represented as relative size compared with tumor size at start of treatment. (b). Concentration of plasma scFv425:sTRAIL in mice treated with Ad-scFv425:sTRAIL (109 vp). (c) Concentration of plasma scFv425:sTRAIL in mice treated with Ad-scFv425:sTRAIL (1010 vp) (d) Concentration of scFv425:sTRAIL in plasma and IP fluid in mice treated with Ad-scFv425:sTRAIL (109vp) at day 64 after infection. In b–d, TRAIL concentrations were determined using TRAIL ELISA. Molecular Therapy 2008 16, 1919-1926DOI: (10.1038/mt.2008.203) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions